ImmunityBio
Prix: 1.69Entreprise et modèle économique
ImmunityBio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. Its core products include novel therapies that leverage the immune system to target tumors and viral infections. The company operates primarily in the healthcare sector, with major revenue sources stemming from research collaborations and potential future product sales. ImmunityBio is currently in the clinical trial phase for several of its therapies, which are aimed at addressing unmet medical needs in oncology and infectious disease treatment.
Profil d’investissement
The investment profile of ImmunityBio suggests it may be more suitable for growth investors, given its focus on innovative therapies and potential future market opportunities. However, the company's significant risks and recent financial performance indicate a high level of uncertainty. Investors should consider their risk tolerance and investment strategy when evaluating this stock.
Métriques fondamentales (expérimental)
- BPA (TTM) — bénéfice par action des 12 derniers mois, $
- -0.58 Risque
- Chiffre d’affaires QoQ — croissance trimestrielle du chiffre d’affaires
- -100.0% ↓
- Surprise BPA
- -16.7% moins bon que prévu
- Volatilité 20 j
- 5.4% normal
Suivre dans le portefeuille
Graphique des prix
| Date | Avant | Après | Raison |
|---|---|---|---|
| 2026-05-08 15:23 | — | Vendre | scenario_deterioration |
| 2026-05-08 05:19 | Vendre | Vendre | scenario_deterioration |
| 2026-04-17 02:46 | Conserver | Vendre | Компания демонстрирует высокую волатильность и отрицательные финансовые показатели, что указывает на значительные риски. Однако недавний рост на 51.80% за 120 дней может свидетельствовать о потенциальных возможностях для |
| Date | Analyste | Action | Objectif | Prix alors |
|---|---|---|---|---|
| 2026-06-08 10:30 | Raymond James | Mettre à jour | — → 5 | 1.82 |
| 2025-10-17 10:19 | Leerink Partners | Mettre à jour | — → 2 | 0.8455 |
Rien pour le moment